A Study of Cetuximab(Erbitux) With Cisplatin and Capecitabine(Xeloda)as 1st Line Treatment in the Advanced Gastric Cancer
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- Tumor response rate
研究概览
简要总结
The purpose of this study is to investigate whether cetuximab (Erbitux®) with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective.
详细描述
Gastric cancer remains one of the major causes of cancer deaths around the world, especially in Asia. Previous study of ML17032 has proved that XP(capecitabine plus cisplatin)is effective in advanced gastric cancer, with the overall response rate of 41%, the median PFS of 5.6 month. Recently, the EGFR monoclonal antibody of cetuximab has shown to be successful in treating advanced colorectal cancer with or without chemotherapy. Since EGFR also express in gastric cancer, A single arm, open, multicenter phase II study of cetuximab in combination with cisplatin and capecitabine as first line treatment in patient with advanced gastric cancer.If applicable, the value of mutations in k-ras, b-raf, P53, and EGFR copy number to predict the clinical response to cetuximab in advanced gastric cancer patients will also be accessed.Tumor tissue from study patients will be checked for k-ras, b-raf, and P53 mutation by sequencing and for EGFR copy number by chromogenic in situ hybridization. DNA will be extracted from paraffin-embedded samples.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Having signed informed consent
- •Age 18 to 75 years old
- •Histologically confirmed gastric adenocarcinoma
- •Unresectable recurrent or metastatic disease
- •Previous neo-adjuvant or adjuvant treatment for gastric cancer, if applicable, more than 12 months
- •Measurable disease according to the RECIST criteria
- •Karnofsky performance status ≥60
- •Life expectancy of ≥2 month
- •No prior radiotherapy except radiotherapy at non-target lesion of the study more than 4 weeks
- •ALT and AST<2.5 times ULN (≤5 times ULN in patients with liver metastases)
- •Serum albumin level ≥3.0g/dL
- •Serum AKP < 2.5 times ULN
- •Serum creatinine <1.5mg/dL
- •Bilirubin level < 1.5mg/dL
- •Serum creatinine <1.5 times ULN
- •WBC>3,000/mm3, absolute neutrophil count ≥2000/mm3, platelet>100,000/mm3, Hb>9g/dl
排除标准
- •Brain metastasis (known or suspected)
- •Previous systemic therapy for metastatic gastric cancer
- •Inability to take oral medication
- •Previous EGFR pathway-targeting therapy
- •Surgery (excluding diagnostic biopsy) within 4 weeks prior to study entry
- •Heart failure, coronary artery disease, myocardial infarction within the last 6 months
- •Known allergy to any study treatment
- •Pregnancy or lactation period
- •Any investigational agent within the past 28 days
- •Other previous malignancy within 5 year, except non-melanoma skin cancer
- •Previous adjuvant therapy with capecitabine+platinum
- •Pre-existing neuropathy>grade 1
- •Legal incapacity
研究组 & 干预措施
C225+Chemotherapy
干预措施: cetuximab, cisplatin, capecitabine (Drug)
结局指标
主要结局
Tumor response rate
时间窗: 1 year
次要结局
- Time to progression Disease control rate Overall survival K-ras, b-raf, p53 gene mutation and EGFR gene copy number vs. tumor response safety(5 year)
研究者
Shen Lin
pro.
Peking University